Title |
RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group
|
---|---|
Published in |
Journal of Clinical Pathology, July 2014
|
DOI | 10.1136/jclinpath-2014-202467 |
Pubmed ID | |
Authors |
Newton ACS Wong, David Gonzalez, Manuel Salto-Tellez, Rachel Butler, Salvador J Diaz-Cano, Mohammad Ilyas, William Newman, Emily Shaw, Philippe Taniere, Shaun V Walsh |
Abstract |
Analysis of colorectal carcinoma (CRC) tissue for KRAS codon 12 or 13 mutations to guide use of anti-epidermal growth factor receptor (EGFR) therapy is now considered mandatory in the UK. The scope of this practice has been recently extended because of data indicating that NRAS mutations and additional KRAS mutations also predict for poor response to anti-EGFR therapy. The following document provides guidance on RAS (i.e., KRAS and NRAS) testing of CRC tissue in the setting of personalised medicine within the UK and particularly within the NHS. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such RAS testing. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Nigeria | 1 | 25% |
Unknown | 3 | 75% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Scientists | 2 | 50% |
Science communicators (journalists, bloggers, editors) | 1 | 25% |
Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Ecuador | 2 | 2% |
United Kingdom | 2 | 2% |
Hong Kong | 1 | 1% |
South Africa | 1 | 1% |
Germany | 1 | 1% |
Unknown | 88 | 93% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 18 | 19% |
Researcher | 17 | 18% |
Student > Master | 15 | 16% |
Student > Ph. D. Student | 11 | 12% |
Student > Postgraduate | 5 | 5% |
Other | 15 | 16% |
Unknown | 14 | 15% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 47 | 49% |
Biochemistry, Genetics and Molecular Biology | 11 | 12% |
Agricultural and Biological Sciences | 9 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
Computer Science | 2 | 2% |
Other | 7 | 7% |
Unknown | 17 | 18% |